Clinical Trial

A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of SHR-3167 at steady state in subjects with type 2 diabetes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-16; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2025-09-09
Trial Details
NCT Number NCT07032688
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Type 2 Diabetes
Enrollment 55 participants
Start Date 2025-08-11
Primary Completion 2027-03 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-17